Slowing the Progression of Chronic Kidney Disease in Patients With Diabetes: Managed Care Interventions to Address Treatment Gaps

Program Description
In recent decades, significant progress has been made in the management of diabetes with novel medications, insulin formulations, and use of technology. However, people with diabetes continue to experience long-term microvascular complications, such as retinopathy and nephropathy. Nephropathy occurs in more than 40% of people with diabetes and is the leading cause of chronic kidney disease (CKD) worldwide; therefore, prevention and optimal management of CKD in diabetes remains a key treatment target. Pharmacists need to be familiar with screening parameters for the early identification and treatment of CKD in patients with diabetes because aggressive management of comorbidities and complications may prevent progression to end-stage renal disease. Optimal management has the potential for cost savings, as progression of CKD and cardiovascular events lead to increased healthcare resource utilization and remain a leading driver of costs for patients with diabetes. The expert panelists will discuss the current landscape of CKD prevention and management including renal protective strategies and emerging treatments.

Target Audience: Managed care pharmacists

Type of Activity: Application
Release date: November 4, 2021
Expiration date: November 4, 2022

Time to complete activity: 1.5 hours
Fee: Free

Educational Objectives

At the completion of this activity, participants will be able to:

• Explain the epidemiology of diabetes and chronic kidney disease (CKD) and the pathology of kidney disease in this population, along with the drivers of CKD progression
• Interpret the current clinical guidelines and data for CKD in type 2 diabetes along with medication recommendations and emerging treatment options aimed at addressing the gaps in care
• Examine the economic and clinical burden of diabetic CKD and opportunities for managed care interventions to improve costs and patient outcomes

Pharmacy Times Continuing Education^™ is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 1.5 contact hours (0.15 CEU) under the ACPE universal activity number 0290-0000-21-383-H01-P. The activity is available for CE credit through November 4, 2022.

Instructions for Completing the Activity and Receiving CPE Credit

To receive CPE credit, participants must complete the pretest, view the webcast in its entirety, complete the posttest, and complete the online activity evaluation. After successful completion of the online activity evaluation, you can submit your credit to CPE Monitor. You may view your credit within 48 hours at www.mycpemonitor.net. All participants must request credit before the activity expiration date. CE credit will not be issued after this date.

Faculty

Rosellen Koshy, PharmD, has no relevant financial relationships with commercial interests to disclose.

Katie Cardone, PharmD, BCACP, FNKF, FASN, FCCP, has the following relevant financial relationships with commercial interests to disclose:
Consultant: Otsuka, Vifor
Spouse: Fresenius

Pharmacy Times Continuing Education^™ Planning Staff—Jim Palatine, RPh, MBA; Maryjo Dixon, RPh; Rose Namissa, PharmD, BCPS; Liz Rauh; Susan Pordon; Brianna Winters; and Chloe Taccetta have no relevant financial relationships with commercial interests to disclose.

Anonymous peer reviewers were used as part of content validation and conflict resolution. The peer reviewers have no relevant financial relationships with commercial interests to disclose.

Educational Disclaimer
CPE activities are offered solely for educational purposes and do not constitute any form of professional advice or referral. Discussions concerning drugs, dosages, and procedures may reflect the clinical experience of the author(s) or they may be derived from the professional literature or other sources and may suggest uses that are investigational in nature and not approved labeling or indications. Participants are encouraged to refer to primary references or full prescribing information resources.

For questions about this internet CPE activity, please contact:
[email protected]
Privacy Policy and Terms of Use Information:
www.pharmacytimes.org/terms